Recombinant Human GLP1R Protein，His

GLP-1 receptor (GLP-1R) agonists have emerged as a pivotal focus in diabetes and obesity research due to their role in glucose metabolism and appetite regulation. Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by the intestines in response to food intake. It enhances insulin secretion from pancreatic beta cells while simultaneously inhibiting glucagon release, thus lowering blood glucose levels. Moreover, GLP-1 promotes satiety and slows gastric emptying, contributing to weight loss. However, the therapeutic potential of GLP-1 is limited by its rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). As a result, the development of GLP-1 receptor (GLP-1R) agonists, which mimic the action of GLP-1 and exhibit resistance to DPP-4, has gained significant attention. These recombinant proteins have shown efficacy in clinical settings, leading to improvements in glycemic control and weight management for individuals with type 2 diabetes and obesity. The structural and functional characterization of GLP-1R, as well as the exploration of its signaling pathways, are critical for enhancing the efficacy of these therapies and understanding their mechanisms of action. Ongoing research is focused on optimizing GLP-1R agonists to improve their pharmacokinetic profiles, minimize side effects, and expand their therapeutic applications beyond diabetes and obesity, making them an indispensable subject of study in metabolic disease management.